Seminoma, a type of testicular cancer that predominantly affects young men, is the most common testicular germ cell tumor and is characterized by its similarity to primordial germ cells (PGCs), the precursor to sperm cells that form early in embryonic development. Despite a generally favorable prognosis with high cure rates through chemotherapy, approximately 10% of seminoma cases exhibit resistance, leading to metastasis and challenging relapses.
Research on seminoma to develop better treatments has been impeded by the lack of relevant mouse models and the scarcity of seminoma samples. Additionally, the tumor itself is complex, with varied cell types and a significant presence of immune cells, making it hard to analyze in bulk.
Kotaro Sasaki
These obstacles hinder comprehensively understanding seminoma's genetic and molecular underpinnings,” says Kotaro Sasaki, a physician scientist at the University of Pennsylvania’s School of Veterinary Medicine who is leading the charge on researching the biology of urogenital cancers at the molecular level.
In a paper published in the journal Cell Reports, a team led by Sasaki and collaborators developed the first in vitro seminoma model andpresented the most comprehensive single-cell atlas of human male germ cell development reported to date, shedding light on chromosomal anomalies and signaling pathways that may contribute to seminoma development.
“Our study, which used samples from various stages of early human male development, has provided key insights,” Sasaki says. “We now better understand the origins, chromosomal anomalies, and signaling pathways involved. And most excitingly, we have developed the first in vitro seminoma model, a vital step toward understanding and potentially treating the disease.”
Read more on Penn Today!